Lineage Cell Therapeutics (LCTX) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Lineage Reports Second Quarter 2021 Financial Results and Highlights Additional Progress From Clinical Cell Therapy Programs
August 12, 2021 4:05 PM EDTOpRegen® Continued to Demonstrate Functional and Anatomical Improvements in Patients with Dry AMD Three Cases of Retinal Tissue Restoration Reported; Longest of Which Has Lasted 3 Years Company Added to Russell 3000® and Russell Microcap® Indexes License Agreement Announced with Immunomic Therapeutics Inc. to Develop New DC-Based Therapeutic New Chief Financial Officer Appointed Cash and Marketable Securities of $68.7M Expected to Support Operations Well Into 2023
CARLSBAD, Calif.--(BUSINESS... More
